Open access
Sep 2026
Nonclinical safety assessment of SBT777101, a CAR-engineered regulatory T cell therapy for autoimmune diseases
A combination of in vivo and NAM-based nonclinical safety framework for CAR-Treg therapies is established and it is demonstrated that CAR engineering of SBT777101 does not introduce new safety liabilities relative to unmodified polyclonal Tregs.
Herve Lebrec, J. Clingan, de Vries Anne-Renée van der Vuurst et al.
· Toxicological Sciences · 0 citations